Veradermics ended the second quarter with approximately $819.9 million in cash, cash equivalents and marketable securities, providing a runway expected to extend into 2030 as its lead hair-loss program moves through multiple late-stage clinical milestones and toward a potential commercial launch.
VDPHL01 is a proprietary extended-release oral minoxidil formulation being developed for both female and male pattern hair loss. Veradermics said the condition affects an estimated 30 million women and 50 million men in the U.S.
For women, enrollment has been completed in Study 306, a 556-participant Phase 2/3 registration-directed trial. Topline results are expected in the first half of 2027. Veradermics also reported positive Phase 2 Study 207 results showing rapid onset and consistent increases in hair count.
For male pattern hair loss, the company expects multiple catalysts in the second half of 2026, including topline results from confirmatory Phase 3 Study 304 and 12-month data from Phase 2/3 Study 302. The cash runway is expected to fund Veradermics through these Phase 3 readouts and preparations for a potential launch of VDPHL01.
KEY QUOTES:
“Veradermics remains well capitalized to execute against these milestones while continuing preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approved, as a foundational treatment for women and men living with pattern hair loss.”
Reid Waldman, M.D., CEO of Veradermics
